Volume 58, Issue 6 pp. 745-758
Research Article

Sculpting infant soothability: the role of prenatal SSRI antidepressant exposure and neonatal SLC6A4 methylation status

Maria A. Gartstein

Corresponding Author

Maria A. Gartstein

Department of Psychology, Washington State University, Pullman, Washington

Correspondence

Maria A. Gartstein, Department of Psychology, Washington State University, P.O. Box 644820, Pullman, WA.

Email: [email protected]

Search for more papers by this author
Kaia V. Hookenson

Kaia V. Hookenson

Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

Search for more papers by this author
Ursula Brain

Ursula Brain

Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

Search for more papers by this author
Angela M. Devlin

Angela M. Devlin

Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

Search for more papers by this author
Ruth E. Grunau

Ruth E. Grunau

Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

Search for more papers by this author
Tim F. Oberlander

Tim F. Oberlander

Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

Search for more papers by this author
First published: 02 June 2016
Citations: 17

Abstract

The role of prenatal Selective Serotonin Reuptake Inhibitor (SSRI) exposure and SLC6A4 promoter methylation status in shaping soothability at 3 and 6 months of age, for infants exposed to antidepressant medication prenatally (n = 46) and those not exposed (n = 69) was investigated. SSRI exposure status and duration of exposure (number of days) were examined along with neonatal methylation status at mean CpG 9,10 and via factor analysis across 10 CpG sites yielding PC1 (CpGs sites: 3,4,5,7) and PC2 (CpG 1,8). Analyses revealed interactions for methylation markers and SSRI exposure variables. A significant interaction between SSRI exposure and mean SLC6A4 methylation at CpG 9,10 and separately for PC1 emerged, controlling for multiple birth/medical and background covariates (e.g., Apgar scores, maternal education). Increased neonatal methylation status was associated with increased soothability changes from 3 to 6 months among infants prenatally exposed to SSRIs.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.